Skip to main content
NCBI home page
Gut logoLink to Gut
. 1991 Nov;32(11):1280–1285. doi: 10.1136/gut.32.11.1280

Healing and prevention of relapse of reflux oesophagitis by cisapride.

J Toussaint 1, A Gossuin 1, M Deruyttere 1, F Hublé 1, G Devis 1
PMCID: PMC1379152  PMID: 1752455

Abstract

Altogether, 138 patients were included in a study aimed at evaluating the effect of cisapride on healing and relapse of oesophagitis shown endoscopically. In the first phase of the study cisapride was given in an open fashion at 10 mg four times a day for 8 to 16 weeks, and healing was obtained in 69% of patients. Healing occurred later in patients with grades II to IV oesophagitis. The total score for reflux symptoms decreased by 67%. Eighty of the healed patients were included in the second phase. They were randomly assigned to double blind treatment with either cisapride 10 mg (n = 37) or placebo (n = 43) twice a day. Control endoscopy was performed when symptoms recurred or at the end of the six month trial. The cumulative percentage of patients in remission was higher (p = 0.06, survival analysis) in the cisapride group than in the placebo group, the relapse rates being 20% and 39%. The duration of remission tended to be longer in patients with a lower initial degree of oesophagitis. Adverse effects were no more frequent with cisapride than with placebo. In conclusion, cisapride is efficacious in healing oesophagitis, and, unlike other gastrointestinal prokinetic drugs or low dose cimetidine (400-800 mg daily) or ranitidine (150 mg daily), it may prevent relapse of oesophagitis.

Full text

PDF
1280

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldi F., Bianchi Porro G., Dobrilla G., Iascone C., Lobello R., Marzio L., Sabbatini F., Tittobello A., Verme G. Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial. J Clin Gastroenterol. 1988 Dec;10(6):614–618. doi: 10.1097/00004836-198812000-00007. [DOI] [PubMed] [Google Scholar]
  2. Behar J., Brand D. L., Brown F. C., Castell D. O., Cohen S., Crossley R. J., Pope C. E., 2nd, Winans C. S. Cimetidine in the treatment of symptomatic gastroesophageal reflux: a double blind controlled trial. Gastroenterology. 1978 Feb;74(2 Pt 2):441–448. [PubMed] [Google Scholar]
  3. Castell D. O. Future medical therapy of reflux esophagitis. J Clin Gastroenterol. 1986;8 (Suppl 1):81–85. [PubMed] [Google Scholar]
  4. Dent J., Holloway R. H., Toouli J., Dodds W. J. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut. 1988 Aug;29(8):1020–1028. doi: 10.1136/gut.29.8.1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dubois A. Clinical relevance of gastroduodenal dysfunction in reflux esophagitis. J Clin Gastroenterol. 1986;8 (Suppl 1):17–25. doi: 10.1097/00004836-198606001-00005. [DOI] [PubMed] [Google Scholar]
  6. Festen H. P., Driessen W. M., Lamers C. B., Van Tongeren J. H. Cimetidine in the treatment of severe ulcerative reflux oesophagitis; results of an 8-week double-blind study and of subsequent long-term maintenance treatment. Neth J Med. 1980;23(6):237–240. [PubMed] [Google Scholar]
  7. Finkelstein W., Isselbacher K. J. Drug therapy: Cimetidine. N Engl J Med. 1978 Nov 2;299(18):992–996. doi: 10.1056/NEJM197811022991806. [DOI] [PubMed] [Google Scholar]
  8. Glise H. Healing, relapse rates and prophylaxis of reflux esophagitis. Scand J Gastroenterol Suppl. 1989;156:57–64. doi: 10.3109/00365528909091039. [DOI] [PubMed] [Google Scholar]
  9. Havelund T., Laursen L. S., Skoubo-Kristensen E., Andersen B. N., Pedersen S. A., Jensen K. B., Fenger C., Hanberg-Sørensen F., Lauritsen K. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J (Clin Res Ed) 1988 Jan 9;296(6615):89–92. doi: 10.1136/bmj.296.6615.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hetzel D. J., Dent J., Reed W. D., Narielvala F. M., Mackinnon M., McCarthy J. H., Mitchell B., Beveridge B. R., Laurence B. H., Gibson G. G. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988 Oct;95(4):903–912. doi: 10.1016/0016-5085(88)90162-x. [DOI] [PubMed] [Google Scholar]
  11. Horowitz M., Hetzel D. J., Buckle P. J., Chatterton B. E., Shearman D. J. The effect of omeprazole on gastric emptying in patients with duodenal ulcer disease. Br J Clin Pharmacol. 1984 Nov;18(5):791–794. doi: 10.1111/j.1365-2125.1984.tb02544.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Janisch H. D., Hüttemann W., Bouzo M. H. Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepatogastroenterology. 1988 Jun;35(3):125–127. [PubMed] [Google Scholar]
  13. Kaul B., Petersen H., Erichsen H., Myrvold H. E., Grette K., Halvorsen T., Fjøsne U. Gastroesophageal reflux disease. Acute and maintenance treatments with cimetidine. Scand J Gastroenterol. 1986 Mar;21(2):139–145. doi: 10.3109/00365528609034638. [DOI] [PubMed] [Google Scholar]
  14. Koelz H. R., Birchler R., Bretholz A., Bron B., Capitaine Y., Delmore G., Fehr H. F., Fumagalli I., Gehrig J., Gonvers J. J. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986 Nov;91(5):1198–1205. doi: 10.1016/s0016-5085(86)80017-8. [DOI] [PubMed] [Google Scholar]
  15. Koop H., Mönnikes H., Koop I., Dionysius J., Schwarz C., Arnold R. Effect of the prokinetic drug cisapride on gastrointestinal hormone release. Scand J Gastroenterol. 1986 Oct;21(8):907–913. doi: 10.3109/00365528608996394. [DOI] [PubMed] [Google Scholar]
  16. Lieberman D. A. Medical therapy for chronic reflux esophagitis. Long-term follow-up. Arch Intern Med. 1987 Oct;147(10):1717–1720. [PubMed] [Google Scholar]
  17. McCallum R. W., Prakash C., Campoli-Richards D. M., Goa K. L. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs. 1988 Dec;36(6):652–681. doi: 10.2165/00003495-198836060-00002. [DOI] [PubMed] [Google Scholar]
  18. Meier P. B., Ansel H. J., Shafer R. B., Duane W. C. Efficacy of chenodeoxycholic acid and ursodeoxycholic acid for lowering cholesterol saturation index of gallbladder in patients with a sphincterotomy. Gastroenterology. 1988 Dec;95(6):1595–1600. doi: 10.1016/s0016-5085(88)80083-0. [DOI] [PubMed] [Google Scholar]
  19. Meuwissen S. G., Klinkenberg-Knol E. C. Treatment of reflux oesophagitis with H2-receptor antagonists. Scand J Gastroenterol Suppl. 1988;146:201–213. doi: 10.3109/00365528809099147. [DOI] [PubMed] [Google Scholar]
  20. Pedersen S. A., Kraglund K., Vinter-Jensen L. The effects of omeprazole on gastro-oesophageal sphincter pressure, intragastric pH, and the migrating motor complex in fasting healthy subjects. Scand J Gastroenterol. 1987 Aug;22(6):725–730. doi: 10.3109/00365528709011150. [DOI] [PubMed] [Google Scholar]
  21. Richter J. E. A critical review of current medical therapy for gastroesophageal reflux disease. J Clin Gastroenterol. 1986;8 (Suppl 1):72–80. doi: 10.1097/00004836-198606001-00011. [DOI] [PubMed] [Google Scholar]
  22. Robertson D. A., Aldersley M. A., Shepherd H., Lloyd R. S., Smith C. L. H2 antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response? Gut. 1987 Aug;28(8):946–949. doi: 10.1136/gut.28.8.946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sandmark S., Carlsson R., Fausa O., Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol. 1988 Jun;23(5):625–632. doi: 10.3109/00365528809093923. [DOI] [PubMed] [Google Scholar]
  24. Sandmark S., Carlsson R., Fausa O., Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol. 1988 Jun;23(5):625–632. doi: 10.3109/00365528809093923. [DOI] [PubMed] [Google Scholar]
  25. Scarpignato C. Pharmacological bases of the medical treatment of gastroesophageal reflux disease. Dig Dis. 1988;6(3):117–148. doi: 10.1159/000171190. [DOI] [PubMed] [Google Scholar]
  26. Sherbaniuk R., Wensel R., Bailey R., Trautman A., Grace M., Kirdeikis P., Jewell L., Pare P., Levesque D., Farley A. Ranitidine in the treatment of symptomatic gastroesophageal reflux disease. J Clin Gastroenterol. 1984 Feb;6(1):9–15. [PubMed] [Google Scholar]
  27. Tytgat G. N., Nio C. Y. The medical therapy of reflux oesophagitis. Baillieres Clin Gastroenterol. 1987 Oct;1(4):791–807. doi: 10.1016/0950-3528(87)90019-4. [DOI] [PubMed] [Google Scholar]
  28. Verlinden M. Review article: a role for gastrointestinal prokinetic agents in the treatment of reflux oesophagitis? Aliment Pharmacol Ther. 1989 Apr;3(2):113–131. doi: 10.1111/j.1365-2036.1989.tb00197.x. [DOI] [PubMed] [Google Scholar]
  29. Wallin L., Madsen T., Boesby S. Gastro-oesophageal function in normal subjects after oral administration of ranitidine. Gut. 1983 Feb;24(2):154–157. doi: 10.1136/gut.24.2.154. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES